London · Delayed Price · Currency is GBP · Price in GBX Optima Health Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 17% to GBP 59.5 million in H1 2026, driven by acquisitions and organic growth, with strong new business wins and robust cash generation. Strategic initiatives and transformation programs are underway to boost margins and reach medium-term targets, supported by a stable competitive landscape.
Fiscal Year 2025
-
FY 2025 saw revenue dip to GBP 105 million due to contract changes, but underlying growth was 4.1% and EBITDA margin improved to 16.7%. Net debt dropped sharply post-demerger, and record new business wins, including a major UK Armed Forces contract, position the company for strong future growth.
-
Reported resilient H1 FY2025 results with £50.8m revenue and 17% EBITDA margin, despite prior contract losses. New business wins and a strong pipeline support 4% organic growth, while net debt fell to £0.6m. Margin expansion and further growth are targeted as integration and restructuring are complete.